Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 6/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4769805 | 0.94 | HDAC2 (0.62) | HDAC2HDAC8HDAC6HDAC1ALOX5 | |
| SCHEMBL2496845 | 0.88 | HDAC2 (0.55) | HDAC2HDAC8HDAC6HDAC1ALOX5 | |
| SCHEMBL1585361 | 0.81 | CYP1A2 (0.44) | HDAC2HDAC8HDAC6HDAC1ALOX5 | |
| SCHEMBL6981878 | 0.80 | KCNH2 (0.52) | HDAC2HDAC8HDAC6HDAC1ALOX5 | |
| SCHEMBL7415148 | 0.78 | ALOX5 (0.51) | HDAC2HDAC8HDAC6HDAC1ALOX5 | |
| SCHEMBL10932714 | 0.77 | ALOX5 (0.58) | HDAC2HDAC8HDAC6HDAC1ALOX5 | |
| SCHEMBL25950098 | 0.77 | ALOX5 (0.58) | HDAC2HDAC8HDAC6HDAC1ALOX5 | |
| SCHEMBL5548324 | 0.77 | AOC3 (0.58) | ADRA1ASLC6A3CHRM2HTR1AADRA2A | |
| SCHEMBL6232723 | 0.77 | AOC3 (0.58) | ALOX5ADRA1ASLC6A3CHRM2HTR1A | |
| SCHEMBL5540861 | 0.76 | SIGMAR1 (0.47) | ALOX5ADRA1ASLC6A3CHRM2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115605-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-03 | — | — | US | claimed |
| WO-2001085170-A9 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-01-26 | — | — | WO | claimed |
| US-20040192719-A1 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | claimed |
| US-20040053932-A1 | Peptide deformylase inhibtors | GLAXOSMITHKLINE LLC | 2004-03-18 | — | — | US | claimed |
| CN-107875145-A | A kind of compound α ketone acids piece and its preparation technology | 浙江昂利康制药股份有限公司 | 2018-04-06 | — | — | CN | disclosed |
| EP-1283711-B1 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2008-03-19 | — | — | EP | disclosed |
| US-7115605-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2001085170-A9 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-01-26 | — | — | WO | disclosed |
| EP-1534281-A1 | N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE) | Astrazeneca AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| US-6806369-B2 | N-FORMYL-N-HYDROXY-2-(5-ISOQUINOLINOXY)ETHYLAMINE ANTI-BACTERIAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2004-10-19 | — | — | US | disclosed |
| US-20040192719-A1 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | disclosed |
| US-20040053932-A1 | Peptide deformylase inhibtors | GLAXOSMITHKLINE LLC | 2004-03-18 | — | — | US | disclosed |
| WO-2004006925-A1 | N-SULFONYLPIPERIDINES AS METALLOPROTEINASE INHIBITORS (TACE) | ASTRAZENECA AB (SE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053932-A1 | Peptide deformylase inhibtors | PDF, VIP, SPPL2B | HDAC2 3662/4885HDAC8 3540/4885HDAC6 776/4885 |
| US-20040192719-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | HDAC2 3549/4885HDAC8 2220/4885HDAC6 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.